Related by context. All words. (Click for frequent words.) 82 multiple ascending dose 74 dose escalation trial 73 Phase Ia 72 dose escalation study 71 Phase 1a 70 Phase 1b clinical 70 ascending doses 69 dose escalation Phase 69 Phase 1b trial 69 Phase 1b 69 placebo controlled 68 Phase 2a clinical 68 Phase 2b study 68 Phase Ib 68 Phase 2a trial 68 pharmacokinetics PK 67 Phase Ib clinical 67 randomized placebo controlled 67 phase IIa 67 safety tolerability 66 safety tolerability pharmacokinetics 66 controlled dose escalation 66 dose escalation clinical 66 Phase 2b trial 66 Phase III clinical 66 Phase IIa clinical 66 dose dose escalation 66 Phase IIa 65 Phase IIa trial 65 Phase 1a clinical 65 blind randomized placebo 65 double blind placebo 65 Phase IIb 65 blinded placebo controlled 65 pharmacokinetic studies 64 placebo controlled Phase 64 pivotal Phase III 64 Phase IIb clinical 64 pharmacokinetic 64 phase IIb 64 randomized double 64 pharmacokinetics 64 Phase 2a 64 IIa trial 64 ascending dose 64 multicenter randomized double 64 Phase IIa trials 64 double blinded placebo 64 pharmacodynamic profile 64 blinded randomized placebo controlled 63 Phase IIb trial 63 placebo controlled clinical 63 placebo controlled randomized 63 Phase Ib II 63 randomized Phase III 63 Phase Ib study 63 phase Ib 63 GetGoal Phase III 63 desvenlafaxine succinate 63 phase 2a 63 multicenter randomized placebo controlled 63 pharmacodynamics 63 controlled multicenter 63 blind placebo controlled 62 placebo controlled Phase III 62 pharmacokinetic profile 62 evaluating tivozanib 62 multicenter Phase II 62 NOX E# 62 pharmacokinetic PK 62 blind randomized 62 dyskinesia PD LID 62 TMC# C# 62 safety tolerability pharmacokinetic 62 confirmatory Phase III 62 double blinded randomized 62 Phase 2b clinical 62 phase IIa clinical 62 phase IIb clinical 62 phase IIb study 62 randomized controlled 62 dosing cohort 61 Phase Ib clinical trials 61 Phase #b/#a 61 INCB# [001] 61 masked placebo controlled 61 pharmacokinetic pharmacodynamic 61 multicenter Phase 61 maximally tolerated dose 61 Phase IIIb clinical 61 PD LID 61 treatment naive genotype 61 VICTOR E1 61 blinded randomized 61 multicentre randomized 60 lead Aganocide compound 60 MEND CABG 60 Pharmacokinetics PK 60 placebo controlled dose escalation 60 dosing cohorts 60 multicentre randomized double 60 tolerability 60 multicenter phase 60 subcutaneously administered 60 multicenter placebo controlled 60 randomized multicenter 60 dose escalation 60 active comparator 60 R#/MEM # 60 pharmacokinetic PK study 60 Phase #/#a 60 Phase IIb trials 60 Initiate Phase 60 Phase #b/#a trial 60 pharmacodynamic effects 60 Multiple Ascending Dose 60 generation PNP inhibitor 60 pharmacodynamic PD 60 ORMD 60 Parkinson disease levodopa induced 60 REVIVE Diabetes 60 Sym# 60 AIR CF1 60 label dose escalation 60 Phase III pivotal 60 PDE4 inhibitor 60 Phase 2b 60 IIa clinical 60 Phase III 60 tolerated dose MTD 60 RSD# oral 60 blind placebo 60 Alzhemed TM 60 multicenter Phase III 59 HCV SPRINT 59 administered subcutaneously 59 Androxal TM 59 blind multicenter 59 preclinical efficacy 59 randomized controlled multicenter 59 clinical trial 59 teriflunomide 59 randomized clinical 59 polymerase inhibitor 59 prospective observational 59 orally bioavailable 59 nucleotide analog 59 multicenter randomized 59 ADVANCE PD 59 oral prodrug 59 #mg QD [002] 59 Phase 2a clinical trials 59 dose pharmacokinetic 59 trodusquemine 59 MEND CABG II 59 Phase IIIb 59 melphalan prednisone 59 IIa clinical trial 59 PRECiSE 59 Phase III placebo controlled 59 Phase 1b dose escalation 59 Phase IIB 59 phase IIb trial 59 Phase III randomized 59 phase Ib clinical 59 IDX# 59 viral kinetic 59 randomized #:# 59 SCH # 59 BRIM2 59 PSN# [002] 58 randomized Phase 2b 58 DermaVir Patch 58 transcriptase inhibitor NNRTI 58 Laquinimod 58 initiate Phase IIa 58 dose cohort 58 LibiGel Phase III 58 APEX PD 58 IIa trials 58 treatment naïve genotype 58 Kahalalide F 58 doxorubicin cyclophosphamide 58 Initiated Phase 58 thorough QT 58 JAK inhibitor 58 Blinatumomab 58 NO# [002] 58 II Clinical Trial 58 Plicera 58 pharmacokinetic PK profile 58 non nucleoside inhibitor 58 telaprevir dosed 58 APTIVUS 58 INSPIRE Trial Phase III 58 randomized 58 HGS# 58 PRTX 58 TG MV 58 ongoing Phase 1b 58 TMC# [002] 58 randomized Phase 58 pivotal bioequivalence 58 XIENCE V Stent System 58 solithromycin 58 Phase III clinical trials 58 Phase 2b clinical trials 58 Phase III confirmatory 58 multicentre 58 Phase II 58 cathepsin K inhibitor 57 randomized controlled clinical 57 BRIM3 57 antibody MAb 57 CG# [003] 57 EDEMA3 57 REG2 57 relapsed MM 57 pramlintide 57 Omacetaxine mepesuccinate 57 registrational trial 57 dose cohorts 57 randomized Phase IIb 57 MIRCERA 57 CCR5 antagonist 57 oral rivaroxaban 57 urocortin 2 57 multicenter randomized controlled 57 mcg dose 57 teduglutide 57 HCV nucleotide polymerase inhibitor 57 multicenter 57 randomized blinded 57 pharmacodynamic 57 fosbretabulin 57 initiated Phase Ib 57 label multicenter 57 initiate Phase IIb 57 By JENNIFER LEARN 57 CTA# Injection 57 Traficet EN 57 nucleoside analog 57 CHAMPION PCI 57 Phase IIA 57 pharmacologically active isomer 57 trastuzumab emtansine T DM1 57 GLP toxicology studies 57 SPIRIT FIRST 57 pharmacodynamics PD 57 huN# DM1 57 NOXAFIL Oral Suspension 57 LB# [003] 57 pomalidomide 57 albiglutide 57 ataluren 57 prasterone 57 8mg/kg 57 statistically significant efficacy 57 Phase III Pivotal 57 multicenter clinical 57 nitazoxanide 57 primary hypercholesterolemia 57 randomized crossover 57 elotuzumab 57 ritonavir boosted 57 Phase 1b clinical trials 57 CCR5 mAb 57 Cloretazine 57 mertansine 57 recurrent glioblastoma multiforme 57 multicenter prospective 57 Phase Ib IIa 57 RG# [001] 57 GAMMAGARD 57 CIMZIA TM 57 KRN# 56 azilsartan medoxomil 56 prospective randomized multicenter 56 investigational protease inhibitor 56 mg BID 56 RDEA# 56 selective androgen receptor modulator 56 Cloretazine R VNP#M 56 CERVARIX 56 Quinamed 56 ascending dose study 56 ANCHOR trial 56 orally dosed 56 Imprime PGG 56 GOUT 56 phase IIIb 56 pivotal Phase 56 Aptivus ® 56 Phase III randomized controlled 56 novel histone deacetylase 56 dose escalation phase 56 initiate Phase 2b 56 posaconazole 56 mg dose 56 Prodarsan ® 56 alvespimycin 56 LEXIVA r 56 APTIVUS r 56 investigational compound 56 DLTs 56 Phase 2b randomized 56 ABSORB clinical 56 QLT# 56 sunitinib malate 56 blind randomized controlled 56 COMFORT II 56 Sapacitabine 56 CRLX# 56 PRT# 56 Prodarsan 56 HGS ETR1 56 HCV infected 56 confirmatory clinical 56 peginterferon alfa 2b 56 ABSORB trial 56 Posiphen 56 refractory CLL 56 Zoraxel 56 Bezielle 56 IMA# 56 daily subcutaneous injections 56 prospective multicenter randomized 56 μg dose 56 ZYBRESTAT fosbretabulin 56 FOLFOX6 chemotherapy regimen 56 mGluR5 NAM 56 MGd 56 atazanavir ritonavir 56 Phase III Clinical Trial 56 Phase IIb Trial 56 subcutaneous dose 56 CK # 56 EURIDIS 56 oral ridaforolimus 56 liposomal formulation 56 Phase III multicenter 56 bevirimat Study 56 XOMA 3AB 56 LCP Tacro 56 evaluating mipomersen 56 intermittent dosing 56 designated HVTN 56 autoantibody positive 56 Randomized Phase II 56 Hsp# Inhibitor 56 mg TID 56 pegylated interferon alpha 56 IND enabling 55 Presents Preclinical 55 eosinophilic asthma 55 ENVISION 55 pharmacokinetic parameters 55 hyaluronidase enzyme 55 Anturol TM 55 FFNS 55 VNP#M 55 Ophena TM 55 MERLIN TIMI 55 ENDEAVOR IV 55 REVLIMID lenalidomide 55 Phase III metastatic melanoma 55 CLL8 55 dose limiting toxicities 55 virus HCV protease inhibitor 55 randomized multicenter trial 55 μg kg 55 MEK inhibitor 55 investigational oral 55 Study Evaluating 55 intravenous bolus 55 tasimelteon 55 Pegasys plus Copegus 55 HIV uninfected 55 Tasimelteon 55 interferon gamma 1b 55 glatiramer acetate 55 cannabinor 55 BIM #A# 55 orally administered 55 HCV NS5B polymerase 55 placebo controlled clinical trials 55 Dose Escalation Study 55 AEG# 55 darunavir ritonavir 55 telaprevir dosing 55 pitavastatin 55 relapsed refractory multiple myeloma 55 ofatumumab 55 virus HCV infection 55 EQUATE OB 55 midstage clinical 55 vidofludimus 55 Phase IIb clinical trials 55 CIMZIA TM certolizumab pegol 55 forodesine 55 Diamyd R 55 nab paclitaxel 55 Phase IIIb study 55 demonstrated antitumor activity 55 Sprague Dawley rats 55 TRO# 55 rALLy clinical trial 55 Initiates Phase II 55 AEGR 55 KRAS mutations occur 55 LAB CGRP 55 prospective randomized controlled 55 GLPG# 55 pertuzumab 55 tenofovir emtricitabine 55 Phase lll 55 Ostarine 55 prospective cohort 55 subcutaneous formulation 55 Aflibercept 55 budesonide foam 55 CIMZIA ™ 55 Zenvia TM 55 topical gel formulation 55 prospective randomized placebo 55 anti leukemic 55 orally administered synthetic retinoid 55 sorafenib Nexavar ® 55 Amrubicin 55 initiate Phase 55 AERAS-#/Crucell Ad# 55 YONDELIS 55 TBC# 55 neratinib 55 CTA# 55 tanespimycin 55 trastuzumab Herceptin R 55 antiviral activity 55 prospective randomized 55 Tarceva TM 55 lomitapide 55 ACTEMRA TM 55 AZILECT R 55 Phase #b/#a clinical 55 Valortim R 55 CANCIDAS 55 TACI Ig 55 HCD# [002] 55 prucalopride 55 MVA MUC1 IL2 55 relapsing remitting multiple sclerosis 55 crizotinib PF # 55 PPAR gamma agonist 55 Randomized Phase 55 multinational multicenter randomized 55 Randomized Double Blind Placebo 55 BENICAR HCT 55 pegylated liposomal doxorubicin 55 huC# DM4 55 PSMA ADC 55 Pivotal Study 55 budesonide MMX ® 55 DDP# 55 ganetespib 55 DEB# 55 symptomatic BPH 55 Board DSMB 55 Antiviral Activity 55 investigational drug 55 LymphoStat B TM 55 Zemplar Capsules 55 fistulizing Crohn disease 55 NCCTG 55 DU #b 55 initiate Phase 1b 55 Peginterferon 55 albinterferon alfa 2b 55 PA# [002] 55 inhaled formulation 55 Triolex 55 diagnosed Ph + 55 Onrigin 55 miconazole Lauriad ® 54 randomized controlled Phase 54 mg administered orally 54 Zenvia ™ 54 docetaxel Taxotere R 54 stated Michelle Berrey 54 Phase IIa clinical trials 54 bendamustine 54 highly immunogenic 54 midstage trials 54 brivaracetam 54 selective modulator 54 RSD# 54 Prosaptide 54 HCV RESPOND 2 54 BENICAR 54 pharmacokinetics pharmacodynamics 54 davunetide intranasal AL 54 HGS ETR2 54 antiretroviral naive 54 PHX# 54 PRX # 54 hGH CTP 54 serotonin norepinephrine reuptake inhibitor 54 dextromethorphan quinidine 54 oral deforolimus 54 multicenter multinational 54 cell lymphoma CTCL 54 Ozarelix 54 thymalfasin 54 placebo controlled studies 54 receptor tyrosine kinase inhibitor 54 CLIRS trial 54 prospective multicenter 54 oral methylnaltrexone 54 mg/m2 cohort 54 Aurora kinase inhibitor 54 Actilon 54 ORACLE MS 54 registrational Phase 54 sorafenib Nexavar 54 generation Hsp# inhibitor 54 Clinical Study 54 vinca alkaloid 54 relapsing multiple sclerosis 54 PROSTVAC VF 54 CIMZIA R 54 randomized blinded placebo 54 clinical pharmacology studies 54 methylnaltrexone bromide 54 lanthanum carbonate 54 boosted protease inhibitor 54 topical formulation 54 randomized controlled trial 54 #mg/day [001] 54 MAA submission 54 Pharmacokinetic 54 somatostatin analog 54 LY# [002] 54 oral formulation 54 BCR ABL inhibitor 54 VEGFR2 inhibitor 54 CEQ# 54 PEG IFN 54 BLA submission 54 transient insomnia 54 mixed hyperlipidemia 54 Luteinizing Hormone Releasing Hormone 54 #mg dose [003] 54 Triapine 54 PF # [001] 54 Phase III trials 54 HCV genotype 1 54 decitabine 54 immunosuppressive compound 54 NEBIDO 54 Sorafenib HCC Assessment 54 baminercept 54 RezularTM 54 immunogenicity 54 Cloretazine ® 54 lorvotuzumab mertansine 54 maturation inhibitor 54 AKT inhibitor 54 ALN VSP Phase 54 GSK# [001] 54 Prostate Lung Colorectal 54 NGX# 54 SAR# [004] 54 ritonavir boosted atazanavir 54 basal bolus regimen 54 tipranavir r 54 Solulin 54 MVax 54 Elvitegravir 54 plus Copegus R 54 RE SURGE 54 hyperphenylalaninemia HPA due 54 Phase 54 intravenously administered 54 mg kg BID 54 Engerix B 54 Phenoptin 54 Omacetaxine 54 evaluable subjects 54 ALISTA 54 KSP inhibitor 54 intravenous dosing 54 Randomized Double blind 54 randomized multicenter Phase III 54 laquinimod 54 HuMax EGFr 54 #mg dose [001] 54 selective S#P# receptor agonist 54 APEX AMI trial 54 randomized #:#:# 54 mg QD 54 label multicenter randomized 54 AVADO 54 relapsed refractory 54 AIR CF2 54 confirmatory Phase 3 54 HBeAg positive 54 Presents Positive 54 LEVADEX 54 controlled multicenter Phase 54 carboplatin paclitaxel 54 PEG PAL 54 registrational 54 phase IIb III 54 Elagolix 54 rNAPc2 54 mcg doses 54 AGILECT R 54 metformin sulfonylurea 54 null responder HCV 54 PEGylated anti 54 ApoB SNALP 54 coadministration 54 Spiegelmer ® 54 cutaneous T 54 Protease Inhibitor 54 CK # administered 54 Metabolic Efficiency 54 bicifadine 54 SUCCEED trial 54 assessing T DM1 54 QD dosing 54 placebo PBO 54 CALGB # [002] 54 multicenter randomized Phase 54 iniparib 54 Phase 2b monotherapy 54 prospective multicentre 54 opioid naive 54 LUX Lung 54 velafermin 54 Trodusquemine 54 PXD# 54 Phase IIa proof 54 docetaxel chemotherapy 54 heavily pretreated 54 Phase IIb III 54 Thorough QT 54 axitinib 54 allosteric modulator NAM 54 lenalidomide Revlimid R 54 metreleptin 54 Triapine R 54 EmbraceAC 54 relapsed refractory AML 54 mg/m2 dose 54 venlafaxine XR 54 #mg/m# [001] 54 Adalimumab 54 dexpramipexole 54 Clinical Trial Evaluating 54 PANVAC VF 54 Testosterone MDTS R 54 TEMSO 54 Meets Primary Endpoint 54 diabetic neuropathic pain 53 acyclovir Lauriad R 53 Ophena 53 BiTE R 53 sNDA submission 53 immunomodulator 53 AAG geldanamycin analog 53 IPL# 53 IMGN# 53 lispro 53 HuMax CD4 53 CLARITY study 53 VA# [002] 53 Phase III Psoriasis 53 R# #mg BID 53 mg kg dose 53 Phase III psoriasis 53 highly selective inhibitor 53 mGluR2 positive 53 unique alkylating agent 53 landmark ATHENA 53 LymphoStat B belimumab 53 Inhalation Solution 53 CALGB 53 VELCADE melphalan 53 Nasdaq PGNX today 53 SNT-MC#/idebenone 53 lintuzumab 53 enzastaurin 53 CRx 53 erlotinib Tarceva ® 53 humanized monoclonal antibody 53 PREOS R 53 VITAL Trial 53 systemically administered 53 receiving INTRON 53 IMC A# 53 bepotastine besilate nasal spray 53 ZOLINZA 53 achieved statistical significance 53 pDNA vaccine 53 Velcade bortezomib 53 OPT CHF 53 tgAAC# 53 protease inhibitor PI 53 Tezampanel 53 Oral NKTR 53 EXPLORE Xa 53 Dose escalation 53 initiate Phase Ib 53 evaluable patients 53 plasma pharmacokinetics 53 pan histone deacetylase 53 PRIMO CABG 53 PRX# 53 humanized anti 53 bolus injection 53 preclinical studies 53 celgosivir 53 hypoxia activated prodrug 53 GLYX 53 oral renin inhibitor 53 chlorambucil 53 RE LY ® 53 PEGINTRON TM 53 PS# [001] 53 TMC# r 53 Testosterone MDTS ® 53 SUTENT ® 53 DSMB 53 HDAC Inhibitor 53 evaluating satraplatin 53 methotrexate MTX 53 EQUIP OB 53 Valtropin 53 LibiGel ® 53 Dacogen injection 53 rhIGF-I/rhIGFBP-3 53 mGluR5 negative 53 paclitaxel poliglumex 53 TAXOTERE R 53 IND submission 53 COU AA 53 Multimeric 53 Capesaris 53 decompensated liver disease 53 JANUVIA 53 Vernakalant 53 Aryplase 53 substudy 53 PEG Interferon lambda 53 galiximab 53 ruxolitinib 53 bile duct tumor 53 TBC M4 53 GRNVAC1 53 favorable pharmacokinetic profile 53 satraplatin Phase 53 multicenter study 53 AVOREN 53 histone deacetylase HDAC inhibitor 53 CLIRS 53 ILLUMINATE 53 bapineuzumab AAB 53 COPEGUS ribavirin 53 Multicentre 53 pegylated interferon alfa 2a 53 miglustat 53 intranasal formulation 53 PNP inhibitor 53 prospectively defined 53 ROCKET AF 53 Diamyd ® 53 Vascular Disrupting Agent 53 elacytarabine 53 octreotide implant 53 HQK 53 ibandronate 53 TRX1 53 Ovarian PLCO Cancer 53 Blind Placebo Controlled Trial 53 Completes Enrollment 53 KNS # 53 evaluating REVLIMID 53 placebo controlled multicenter 53 preclinical toxicology 53 pharmacokinetic characteristics 53 CATIE AD 53 nonclinical studies 53 Pivotal Phase III 53 drug pipeline TAFA# 53 fluticasone furoate 53 pharmacokinetic profiles 53 NPH insulin 53 LCP AtorFen 53 long acting muscarinic 53 efavirenz EFV 53 COSIRA trial 53 Folfox 53 CB2 selective receptor agonist 53 sequential dose escalation 53 Sanofi Pasteur Fluzone 53 RG# ITMN 53 ZYBRESTAT 53 Fx #A 53 Pimavanserin 53 topically administered 53 receptor inhibitor 53 immunomodulatory therapy 53 Ceplene/IL-2 53 mg kg cohorts 53 SILENOR TM 53 PARTNER Trial 53 NLX P# 53 Maribavir 53 Seliciclib 53 investigational humanized monoclonal antibody 53 sodium glucose cotransporter 53 Pivotal Phase 53 HPTN 53 Amigal 53 dexamethasone Decadron 53 tolerability profile 53 FAME Study 53 Phase IIa Clinical Trial 53 CDP# 53 aflibercept 53 Corlux 53 metformin XR 53 peripherally acting 53 PREZISTA r 53 Randomized Evaluation 53 Zenvia Phase III 53 Teriflunomide 53 XL# anticancer compounds 53 NXL# 53 beta2 agonist 53 diarrhea predominant irritable 53 mg/m2/day 53 RiVax 53 efficacy endpoint 53 unblinded 53 integrase inhibitor 53 Phase 2a Study 53 Dapagliflozin 53 Denufosol 53 perifosine KRX 53 ACTIVE W 53 Bosutinib 53 estramustine 53 SAR# [002] 53 SCIg 53 PROVENGE ® 53 humanized interleukin 6 53 plus prednisone 53 opioid induced bowel dysfunction 53 dosage regimens 53 JAK2 inhibitor 53 low dose cytarabine 53 Metastatic Melanoma 53 Systemic Sclerosis 53 relapsed myeloma 53 dextofisopam 53 evaluating Vectibix 53 Initiates Phase 53 Phase IIb Clinical Trial 53 TRANSFORMS 53 Genasense ® oblimersen 53 pafuramidine 53 elvitegravir 53 Menerba 53 CELVAPAN H#N# 53 gamma secretase inhibitor 53 rilpivirine 53 hour bronchodilation 53 bortezomib Velcade R 53 evaluating T DM1 53 Completes Patient Enrollment 53 riociguat 53 ChronVac C R 53 SUVN 53 unstable angina UA 53 vicriviroc 53 Archexin 53 Hyphanox 53 ocrelizumab 53 trabectedin 53 mg RDEA# 53 Dextofisopam 53 TAXUS ATLAS 53 aggressive systemic mastocytosis 53 mapatumumab 53 #I TM# 53 rhFVIIa 53 NSABP B 53 Phase III randomized placebo 53 GH deficiency 53 ceftazidime 53 Zerenex 53 safety tolerability pharmacodynamics 53 randomized discontinuation trial 53 eptifibatide 53 TYGACIL 53 Valortim 53 relapsed multiple myeloma 53 BCX# 53 targeted antifolate 53 beta 1a 53 MAGE A3 ASCI 53 oxycodone CR 53 Lodotra TM 53 progressive PsA 53 subcutaneous SC 53 PRIMO CABG2 53 Tanespimycin 53 GSK# [002] 52 3TC lamivudine Epivir 52 tolevamer 52 ACAM FLU 52 EVIZON 52 vivo toxicology 52 UVIDEM 52 IMiDs ® 52 PEGylated Fab fragment 52 pharmacodynamic properties 52 PROVENGE sipuleucel T 52 pegylated alpha interferon 52 Randomised 52 Pharmacokinetic studies 52 weekly subcutaneous injections 52 Phase 2b Clinical Trial 52 Apoptone 52 torezolid phosphate 52 NASDAQ CXSP announced 52 Investigational Oral 52 ELND# 52 tolerability pharmacokinetics 52 PEG INTRON R 52 Proellex TM 52 generation purine nucleoside 52 clinical trials Multikine 52 comparing alemtuzumab 52 metastatic HRPC 52 TO AVOID PREGNANCY WHILE 52 systemic RNAi therapeutic 52 lintuzumab SGN 52 Prospective Randomized 52 quadrivalent HPV vaccine 52 CC genotype 52 selective agonist 52 initiate multicenter 52 LIALDA 52 Melphalan 52 trabedersen 52 Arranon 52 IL# PE#QQR 52 dasatinib Sprycel ® 52 TASKi2 52 Linagliptin 52 evaluable 52 patients evaluable 52 purified inactivated 52 evaluating bafetinib 52 BLOOM DM 52 alemtuzumab Campath 52 bazedoxifene conjugated estrogens 52 alfa 2a 52 mcg albinterferon alfa 2b 52 IPX# 52 eniluracil 52 vapreotide acetate 52 OncoVEX GM CSF 52 TOLAMBA 52 standard chemotherapy regimen 52 SYMMETRY trial 52 ocular formulation 52 intravenous RSD# 52 BOLDER II 52 FOLOTYN ® 52 ARIKACE 52 TELINTRA 52 lexidronam injection 52 NN# [001] 52 Lixivaptan 52 rindopepimut 52 tolerability profiles 52 nucleoside reverse transcriptase inhibitor 52 Ranolazine 52 Degarelix 52 hypercholesterolemic 52 MLN# 52 vitro experiments 52 ADAGIO study 52 metastatic hormone refractory 52 malignant mesothelioma Alfacell 52 Cytarabine Liposome Injection